NEW YORK, NY / ACCESSWIRE / May 14, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Lordstown Motors Corp (NASDAQ:RIDE)
Investors Affected : August 3, 2020 - March 24, 2021
A class action has commenced on behalf of certain shareholders in Lordstown Motors Corp. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's purported pre-orders were non-binding; (ii) many of the would-be customers who made these purported pre-orders lacked the means to make such purchases and/or would not have credible demand for Lordstown's Endurance; (iii) Lordstown is not and has not been "on track" to commence production of the Endurance in September 2021; (iv) the first test run of the Endurance led to the vehicle bursting into flames within 10 minutes; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/lordstown-motors-corp-loss-submission-form/?id=15888&from=1
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)
Investors Affected : June 15, 2020 - April 4, 2021
A class action has commenced on behalf of certain shareholders in Acadia Pharmaceuticals Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/acadia-pharmaceuticals-inc-loss-submission-form/?id=15888&from=1
Churchill Capital Corp IV (NYSE:CCIV)
Investors Affected : January 11, 2021 - February 22, 2021
A class action has commenced on behalf of certain shareholders in Churchill Capital Corp IV. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Lucid was not prepared to deliver vehicles by spring of 2021; (2) Lucid was projecting a production of 557 vehicles in 2021 instead of the 6,000 vehicles touted in the run-up to the merger with Churchill; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
Shareholders may find more information at https://securitiesclasslaw.com/securities/churchill-capital-corp-iv-loss-submission-form/?id=15888&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm